<table>
<thead>
<tr>
<th>Phase</th>
<th>Title</th>
<th>Sponsor</th>
<th>Phase 2 Pharmacy</th>
<th>Phase 3 Pharmacy</th>
<th>Sponsor</th>
<th>Sponsors</th>
<th>Contact</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 2</td>
<td>MiST1 Rucaparib</td>
<td>University Hospitals of Leicester NHS Trust</td>
<td>Derriford, Plymouth</td>
<td>Edinburgh</td>
<td>Beatson, Glasgow</td>
<td>Centre, QMU, London</td>
<td>Beatson, Glasgow</td>
<td>Beatson, Glasgow</td>
</tr>
<tr>
<td>Phase 3</td>
<td>MiST2</td>
<td>45 centres in 8 European countries (Belgium, France, Italy, Switzerland, Spain, Austria, Denmark, and Sweden)</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Phase 3</td>
<td>MiST3</td>
<td>54 centres in 15 European countries (Belgium, France, Italy, Spain, Portugal, Denmark, Sweden, the UK, South Korea, and Singapore)</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Phase 3</td>
<td>MiST4</td>
<td>12 centres in 10 countries (Australia, Austria, Belgium, Canada, China, Germany, France, Greece, Italy, and Singapore)</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
</tr>
</tbody>
</table>

**Eligibility Criteria:**
- Patients must have histologically confirmed adenocarcinoma of the lung (bronchial or bronchioalveolar, non-small cell).
- Patients must have stage IIB-IV disease as defined by the 2015 American Joint Committee on Cancer (AJCC) staging system.
- Patients must have a performance status (PS) of 0-1 as per the Eastern Cooperative Oncology Group (ECOG) criteria.
- Patients must have adequate hematological, renal, and hepatic function as per institutional requirements.
- Patients must not have received prior systemic therapy for advanced disease.
- Patients must not have undergone surgical resection of their primary tumor within the past 4 weeks.
- Patients must not have received any radiation therapy to the thorax within the past 4 weeks.
- Patients must not have received any prior systemic therapy for advanced disease.
<table>
<thead>
<tr>
<th>Title</th>
<th>Phase</th>
<th>Type</th>
<th>Description</th>
<th>Centre Details</th>
<th>Sponsor Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemcitabine in Patients With Malignant Pleural Mesothelioma</td>
<td>Phase III</td>
<td>Drug</td>
<td>Efficacy &amp; Safety of rAd-IFN Administered With Celecoxib &amp; Gemcitabine</td>
<td>[Centre details provided]</td>
<td>Royal Brompton and Harefield NHS Foundation Trust</td>
</tr>
<tr>
<td>This study will evaluate intrapleural administration of vector-based IFN at the target site within the pleural cavity. Patients will be randomised to receive either rAd-IFN (some patients): intrapleural injection at the target site, or Gemcitabine: IV on study Day 1. Treatment will continue until disease progression or adverse effects requiring discontinuation. Patients will be randomised to receive either rAd-IFN (some patients): intrapleural injection at the target site, or Gemcitabine: IV on study Day 1. Treatment will continue until disease progression or adverse effects requiring discontinuation.</td>
<td>[Centre details provided]</td>
<td>[Sponsor details provided]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Eligibility Criteria:**
- Age ≥ 18 years
- Pathologically confirmed MPM
- Adequate laboratory values at Screening:
  - Hemoglobin: 10 g/dL
  - Platelet count: ≥ 100,000/µL
  - Neutrophil count: ≥ 1.5 × 10⁹/L
  - Total bilirubin: ≤ 2.0 mg/dL
  - Creatinine: ≤ 1.5 mg/dL (or ≤ 1.1 mg/dL if ≤ 50% of predicted renal function)
  - Sodium: ≥ 125 mEq/L
  - Calcium: ≤ 11.5 mg/dL
  - Alkaline phosphatase: ≤ 3.0 × ULN
  - AST/ALT: ≤ 2 × ULN
- Aged 18 years or older at the time of consent;
- Pathologic confirmation of MPM by biopsy or surgical resection;
- Local or systemic disease; and
- Adequate bone marrow function.

**Exclusion Criteria:**
- Prior to undertaking a full Phase III randomised controlled trial, patients will need to be assessed for eligibility using the trial protocol and have given informed consent. All patients who meet the eligibility criteria will be enrolled in the trial. Patients will be randomised to receive either rAd-IFN (some patients): intrapleural injection at the target site, or Gemcitabine: IV on study Day 1. Treatment will continue until disease progression or adverse effects requiring discontinuation.

**Treatment Schedule:**
- Phase I:
  - All participants will continue to undergo follow-up visits until the completion of the study.

**Drug used:**
- rAd-IFN treatment arm and intrapleural & gemcitabine
- No drugs used (substudy only)